(4R,5R)-4,5-dimethyl-1,3,2-dioxathiolane 2-oxide | 51260-47-0

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机含氧阴离子化合物
• 英文名称: (4R,5R)-4,5-dimethyl-1,3,2-dioxathiolane 2-oxide
• 英文别名: trans-4,5-Dimethyl-1,3,2-dioxathiolane 2-oxide
• CAS: 51260-47-0
• 化学式: C₄H₈O₃S
• 分子量: 136.172
• InChiKey: SAPINXZHMGNTEC-QWWZWVQMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  54.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (4R,5R)-4,5-dimethyl-1,3,2-dioxathiolane 2-oxide 在 calcium permanganate 、 溶剂黄146 作用下， 生成 4,5-二甲基-1,3,2-二恶噻戊环2,2-二氧化物
  参考文献：
  名称：

  Preparation and Hydrolysis of Some Acetals and Esters of D(—)-2,3-Butanediol

  摘要：

  DOI：

  10.1021/ja01168a033
• 作为产物：
  描述：

  2,3-丁二醇 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 (4R,5R)-4,5-dimethyl-1,3,2-dioxathiolane 2-oxide
  参考文献：
  名称：

  3’-羟基伊曲康唑的用途

  摘要：

  本发明公开了3ˊ-羟基伊曲康唑的用途。3ˊ-羟基伊曲康唑在制备用于降低mTOR信号转导活性的药物中的用途。3ˊ-羟基伊曲康唑降低mTOR信号转导活性，可以用于治疗治疗或预防细胞增殖性疾病，用于治疗和预防癌症，用于预防或调节癌细胞和癌症的转移，用于治疗或预防类风湿关节炎、视网膜病变、黄斑病变、皮肤疾病、红斑狼疮。

  公开号：

  CN105582012A

文献信息

• [EN] BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS<br/>[FR] COMPOSÉS BICYCLIQUES SUBSTITUÉS PAR HÉTÉROARYLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018013774A1

  公开（公告）日：2018-01-18

  Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

  公开了公式(I)至(VIII)的化合物：(I) (II) (III) (IV) (V) (VI) (VII) (VIII)；或其立体异构体、互变异构体、药物可接受的盐、溶剂化物或前药，其中R3是与0至3个R3a取代的双环杂芳基团；且R1、R2、R3a、R4和n在此定义。还公开了使用这些化合物作为PAR4抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物用于抑制或预防血小板聚集，用于治疗血栓栓塞障碍或作为血栓栓塞障碍的初级预防。
• Effect of Methyl Substitution on Conformation and Molecular Arrangement of BEDT-TTF Derivatives in the Crystalline Environment
  作者：Shigeki Matsumiya、Akira Izuoka、Tadashi Sugawara、Tomohiro Taruishi、Yuzo Kawada

  DOI：10.1246/bcsj.66.513

  日期：1993.2

  Two methylated bis(ethylenedithio)tetrathiafulvalene (ET) derivatives, Me2ET and Me4ET were stereoselectively synthesized to examine the effect of methylation on conformations of dihydrodithiin rings and molecular arrangements in the crystalline state. Since the donating ability of Me2ET and Me4ET are similar to that of ET, the methylated ET derivatives are considered to be appropriate to investigate the “lattice pressure” effect on ET radical salts by changing the volume of donor molecules. The upper limit of an activation energy for the ring inversion of the dimethylated dihydrodithiin in solution was estimated to be 32 kJ mol−1 by 13C NMR spectroscopy. The X-ray structure analyses revealed that orientations of methyl groups are fixed to axial in Me2ET and to equatorial in Me4ET, accompanied by the change of molecular stacking. The “volume of a methyl group” was evaluated by comparing the molecular volumes of Me2ET and Me4ET with that of ET, and the effective volume for the axial methyl group turns out to be 15% larger than that of the equatorial. The solid state 13C NMR (CP/MAS) spectra of ET and its derivatives showed that the chemical shifts of resonance lines reflect the conformations of dihydrodithiin rings in crystals.

  立体选择性合成了两种甲基化双(乙撑二硫)四硫富瓦烯 (ET) 衍生物 Me2ET 和 Me4ET，以研究甲基化对二氢二硫环构象和结晶态分子排列的影响。由于Me2ET和Me4ET的供体能力与ET相似，因此甲基化的ET衍生物被认为适合通过改变供体分子的体积来研究对ET自由基盐的“晶格压力”效应。通过 13C NMR 光谱估计溶液中二甲基化二氢二硫因环反转的活化能上限为 32 kJ mol−1。 X射线结构分析表明，Me2ET中甲基的取向固定为轴向，Me4ET中甲基的取向固定为赤道，并伴随着分子堆积的变化。通过比较Me2ET和Me4ET与ET的分子体积来评估“甲基的体积”，结果发现轴向甲基的有效体积比赤道上的有效体积大15%。 ET及其衍生物的固态13C NMR（CP/MAS）谱表明，共振线的化学位移反映了晶体中二氢二硫因环的构象。
• [EN] BENZAMIDE COMPOUND AND USE THEREOF<br/>[FR] COMPOSÉ BENZAMIDE ET SON UTILISATION<br/>[ZH] 苯甲酰胺类化合物及其用途
  申请人：WUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY

  公开号：WO2022068930A1

  公开（公告）日：2022-04-07

  涉及一种有效拮抗P2X3受体的新化合物，其为式（I）所示化合物、其互变异构体、立体异构体、水合物、溶剂化物、药学上可接受的盐或前药，其制备方法，以及其在制备药物中的用途。
• Dihydromaniwamycin E, a Heat-Shock Metabolite from Thermotolerant <i>Streptomyces</i> sp. JA74, Exhibiting Antiviral Activity against Influenza and SARS-CoV-2 Viruses
  作者：Shun Saito、Kayo Funayama、Wataru Kato、Mayu Okuda、Meiko Kawamoto、Teruhiko Matsubara、Toshinori Sato、Akihiko Sato、Satoko Otsuguro、Michihito Sasaki、Yasuko Orba、Hirofumi Sawa、Katsumi Maenaka、Kazutoshi Shindo、Masaya Imoto、Midori A. Arai

  DOI：10.1021/acs.jnatprod.2c00550

  日期：2022.11.25

  and this type of compound has been previously designated a “heat shock metabolite (HSM)” by our research group. Compound 2 is detected as a production-enhanced metabolite at high temperature. Structures of 1 and 2 are elucidated by NMR and MS spectroscopic analyses. The absolute structure of 1 is determined after the total synthesis of four stereoisomers. Though the absolute structure of 2 has been proposed

  二氢马尼瓦霉素 E ( 1 ) 是一种新型马尼瓦霉素衍生物，具有氧化偶氮基部分，是从耐热链霉菌的培养物提取物中分离出来的。 JA74 以及已知的类似物马尼瓦霉素 E ( 2 )。化合物1只能通过菌株JA74在45°C下培养来产生，这种类型的化合物之前被我们的研究小组指定为“热休克代谢物（HSM）”。化合物2在高温下被检测为产量增强的代谢物。 1和2的结构通过NMR和MS光谱分析得到阐明。四种立体异构体全合成后确定1的绝对结构。虽然2的绝对结构被认为与马尼瓦霉素D的结构相同，但2的NMR和旋光值与马尼瓦霉素E的一致。因此，本研究提出对马尼瓦霉素D和马尼瓦霉素D的结构进行修正。 E.化合物1和2显示出针对MDCK细胞的流感(H1N1)病毒感染的抑制活性，显示IC 50值分别为25.7和63.2μM。值得注意的是，当用于感染 293TA 和 VeroE6T 细胞时， 1和2显示出针对 SARS-CoV-2（COVID-19
• Total synthesis of (2R,4S,2′S,3′R)-hydroxyitraconazole: implementations of a recycle protocol and a mild and safe phase-transfer reagent for preparation of the key chiral units
  作者：Gerald J. Tanoury、Robert Hett、H.Scott Wilkinson、Stephen A. Wald、Chris H. Senanayake

  DOI：10.1016/j.tetasy.2003.01.001

  日期：2003.11

  A convergent total synthesis of enantiomerically-pure (2R,4S,2'S,3'R)-hydroxyitraconazole 1b is described. The left dioxolane portion of the molecule was prepared in good yield by the conversion of (S)-10 to the corresponding enantiomerically and diastereomerically-pure acetonide (2R,4R)-3 by a recycle protocol involving diastereoselective crystallization of the tosylate salt, followed by re-equilibration of the mother liquor and crystallization. The right-hand triazolone moeity (2S,3R)-4 was generated by alkyaltion of triazolone 6 with enantiomerically pure cyclic sulfate (4R,5R)-7 under mild and essentially non-hazardous reaction conditions (TDA-1, K2CO3, acetonitrile). (C) 2003 Elsevier Ltd. All rights reserved.